Sino Biological Respiratory Virus Research Toolkit

« Previous article
New CE-Marked ELISA ...

21st December 2020  Product update: rapidmicrobiology staff writer

Large US Rapid Test Manufacturer Streamlines Testing Workflow With Reputable Lab

Innova Medical Group, Inc. (IMG), has acquired California-based Biological Laboratory Inc. (BIOLAB), further strengthening IMG's in-house diagnostic testing and research and development capability in the U.S.

Since 1998, this CLIA-certified clinical laboratory has shown spectacular success in endocrinology, cytology, toxicology, and molecular studies. Most recently, BIOLAB played a key role in COVID-19 molecular (RT-PCR) and antibody (IgM/IgG) testing with its 24-hour turnaround on all routine testing and 2-hour STAT results in emergencies.

BIOLAB is recognized by the American Association of Bioanalysts (AAB), the College of American Pathologists (CAP), and ranks as a Biosafety Level 2 High-Complexity Laboratory.

BIOLAB's approximately 130-employee medical team is comprised of medical doctors, clinical laboratory scientists, bioanalysts, pathologists, microbiologists, and analytical chemists. The company has its own in-house logistics and medical billing division, with experience in all commercial and government insurance plans.

Located only 30 miles from downtown Los Angeles, California, BIOLAB has provided on-site testing services for the entertainment industry and has partnered with whole cities to screen essential workers for COVID-19.

Only 15 miles from IMG's newest manufacturing facility in Brea, California, this acquisition enhances IMG's end-to-end solution as a medical device and services provider. IMG's California footprint adds to its proven presence as the world's largest manufacturer of rapid antigen test kits.

With the unprecedented demand for COVID-19 testing, manufacturers need to fortify supply chains to secure the availability of collection devices, assay reagents, and kits. IMG currently ships greater than 4 million rapid antigen test kits per day and expects to double that volume by year-end.

Adding a CLIA laboratory to IMG's portfolio streamlines testing workflows with accurate and affordable processing. BIOLAB's decades of acquired experience and applied knowledge complements IMG's ability to develop solutions for life-threatening diseases.

IMG plans to significantly expand BIOLAB's testing capability into 2021. BIOLAB will relocate to its new location in Pomona, Calif., in early 2021, adding approximately 100 new jobs to the area. 



Date Published: 21st December 2020

Note: This content has been edited by a rapidmicrobiology staff writer for style and content.

View full company details